Skip to main
GYRE
GYRE logo

GYRE Stock Forecast & Price Target

GYRE Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Gyre Therapeutics Inc. is well-positioned for growth through its acquisition of generic nintedanib, which is expected to enhance its capital resources and solidify its leadership in the idiopathic pulmonary fibrosis (IPF) market. This strategic move is likely to provide significant support for Gyre's operations amid challenging market conditions, reinforcing its commitment to addressing both lung and liver fibrosis through a diverse portfolio of therapies. Additionally, the company’s focus on commercial-stage products and ongoing development of treatments for MASH-associated liver fibrosis exhibits a robust potential for revenue generation in the future.

Bears say

Gyre Therapeutics Inc. faces a negative outlook primarily due to depressed forward multiples, attributed to ongoing market volatility, which raises concerns about the company's valuation. The company's reliance on non-growth stage assets, such as the commercial sales of pirfenidone in China, further exacerbates this issue, as projected revenue generation from these products has plateaued. Additionally, cash burn may pose significant risks, influenced by the stages of development programs and uncertain revenue from potential partnerships or collaborative agreements.

GYRE has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gyre Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gyre Therapeutics Inc (GYRE) Forecast

Analysts have given GYRE a Strong Buy based on their latest research and market trends.

According to 2 analysts, GYRE has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gyre Therapeutics Inc (GYRE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.